STOCK TITAN

Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Stevanato Group S.p.A. (NYSE: STVN) will report its first-quarter financial results on May 9, 2024. The company is a global leader in drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. A conference call and webcast will be held to discuss the financial results.
Stevanato Group S.p.A. (NYSE: STVN) presenterà i risultati finanziari del primo trimestre il 9 maggio 2024. L'azienda è un leader globale nelle soluzioni di contenimento dei farmaci, somministrazione di farmaci e soluzioni diagnostiche per le industrie farmaceutiche, biotecnologiche e delle scienze della vita. Si terrà una conferenza telefonica e un webcast per discutere i risultati finanziari.
Stevanato Group S.p.A. (NYSE: STVN) informará sobre sus resultados financieros del primer trimestre el 9 de mayo de 2024. La compañía es líder mundial en soluciones de contención de medicamentos, entrega de medicamentos y soluciones diagnósticas para las industrias farmacéutica, biotecnológica y de ciencias de la vida. Se realizará una llamada de conferencia y un webcast para discutir los resultados financieros.
Stevanato Group S.p.A. (NYSE: STVN)는 2024년 5월 9일에 첫 번째 분기 재무 결과를 보고할 예정입니다. 이 회사는 제약, 생명공학 및 생명과학 산업을 위한 약물 보관, 전달 및 진단 솔루션 분야에서 글로벌 리더입니다. 재무 결과에 대해 논의하기 위해 컨퍼런스 콜과 웹캐스트가 개최될 예정입니다.
Stevanato Group S.p.A. (NYSE: STVN) annoncera ses résultats financiers du premier trimestre le 9 mai 2024. L'entreprise est un leader mondial dans les solutions de confinement de médicaments, de distribution de médicaments et de solutions diagnostiques pour les industries pharmaceutiques, biotechnologiques et des sciences de la vie. Une conférence téléphonique et un webcast seront organisés pour discuter des résultats financiers.
Stevanato Group S.p.A. (NYSE: STVN) wird am 9. Mai 2024 seine Finanzergebnisse für das erste Quartal vorlegen. Das Unternehmen ist ein global führender Anbieter von Lösungen für Medikamentenkapselung, Medikamentenabgabe und Diagnostiklösungen für die pharmazeutischen, biotechnologischen und Lebenswissenschafts-Industrien. Es wird eine Telefonkonferenz und ein Webcast stattfinden, um die Finanzergebnisse zu besprechen.
Positive
  • None.
Negative
  • None.

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).

Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.

Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: STVN conference call pre-registration.

Webcast: A live, listen-only webcast of the call will be available at the following link: STVN webcast.

Dial in: Those who are unable to pre-register may dial in by calling:

Italy: +39 02 802 09 11
United Kingdom: +44 1 212 818004
United States: +1 718 705 8796
United States Toll Free: +1 855 265 6958

Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: https://hditalia.choruscall.com/?$Y2FsbHR5cGU9MiZpbmZvPWNvbXBhbnk=.

Replay:
The webcast will be archived for three months on the Company’s Investor Relations section of its website.

About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit www.stevanatogroup.com.

Investor Relations

Lisa Miles

lisa.miles@stevanatogroup.com



Media

media@stevanatogroup.com

Source: Stevanato Group S.p.A.

FAQ

When will Stevanato Group S.p.A. (STVN) report its first-quarter financial results?

Stevanato Group S.p.A. (NYSE: STVN) will report its first-quarter financial results on May 9, 2024.

What does Stevanato Group specialize in?

Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries.

What time is the conference call and webcast to discuss the financial results?

The conference call and webcast to discuss the financial results will be held at 8:30 a.m. (ET) on Thursday, May 9, 2024.

How can participants pre-register for the conference call?

Participants can pre-register for the conference call using the following link: STVN conference call pre-registration.

Where can participants find the slide presentation for the call?

The slide presentation will be available on the 'Financial Results' page under the Company's Investor Relations section of its website on the morning of the call.

Stevanato Group S.p.A.

NYSE:STVN

STVN Rankings

STVN Latest News

STVN Stock Data

5.76B
41.66M
2.13%
77.59%
0.87%
Glass Container Manufacturing
Manufacturing
Link
United States of America
Piombino Dese

About STVN

founded in 1949, stevanato group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. it is comprised of two operational divisions: - pharmaceutical systems (ompi and balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. - engineering systems (spami, optrel, innoscan and svm brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. these two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that stevanato group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. the group also benefits from the sglab activ